Aridis To Discuss Topline Data From Phase 3 S. aureus Study On Call On Jan. 25

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webcast on Wednesday, January 25, at 4:15 p.m. ET to provide a business and pipeline update, including a discussion of topline data from the Company’s Phase 3 study of AR-301 in adjunctive treatment of S. aureus ventilator associated pneumonia (VAP). The Company expects to publish topline data from AR-301 on January 25, prior to the call. A question-and-answer session will follow management’s prepared remarks.

Event:	Aridis Pharmaceuticals Corporate Update Conference Call
Date:	Wednesday, January 25, 2023
Time:	4:15 p.m. Eastern Time
Live Call:	+1-877-407-9208 (U.S. Toll-Free) or +1-201-493-6784 (International)
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1588876&tp_key=33c334b81c

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until February 8, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13735220.

https://finance.yahoo.com/news/aridis-pharmaceuticals-discuss-topline-data-133000953.html